Michael Egholm
President & CEO, Director at Standard Biotools Inc. (LAB) since April 2022
Michael Egholm has filed 25 insider reports with the SEC since April 2022, as president & CEO and director at Standard Biotools Inc. (LAB) and director at IsoPlexis Corp (ISO). Michael Egholm made no open-market purchases or sales in the last 12 months. The latest filing, on August 24, 2026, reports shares withheld for taxes or exercise price at Standard Biotools Inc. (LAB).
- Filings
- 25
- Companies
- 2
- Bought on market
- None
- Sold on market
- $15.1K
Companies where Michael Egholm is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| President & CEO, Directorsince April 2022 | 6,137,704 | $15.1K | $0.57 | Aug 24, 2026 | |||
| Director | Jun 21, 2022 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Aug 20, 2026LABPresident & CEO Egholm Michael covered exercise/tax liability with 97,627 shares, decreasing direct ownership by 2% to 6,137,704 units (for tax liability)Form 4Shares withheld for taxes or exercise price
- Aug 3, 2026LABPresident & CEO Egholm Michael covered exercise/tax liability with 362,625 shares, decreasing direct ownership by 5% to 6,235,331 units (tax withholding)Form 4Shares withheld for taxes or exercise price
- May 20, 2026LABPresident & CEO Egholm Michael covered exercise/tax liability with 97,626 shares, decreasing direct ownership by 1% to 6,597,956 units (for withholding tax)Form 4Shares withheld for taxes or exercise price
- Apr 6, 2026LABSEC Form 4 filed by Egholm MichaelForm 4Grant or awardShares withheld for taxes or exercise priceExercise or conversion of a derivative
- Feb 23, 2026LABPresident & CEO Egholm Michael covered exercise/tax liability with 66,127 shares, decreasing direct ownership by 1% to 5,551,710 unitsForm 4Shares withheld for taxes or exercise price
- Nov 20, 2025LABPresident & CEO Egholm Michael covered exercise/tax liability with 63,529 shares, decreasing direct ownership by 1% to 5,617,837 unitsForm 4Shares withheld for taxes or exercise price
- Aug 20, 2025LABPresident & CEO Egholm Michael covered exercise/tax liability with 54,919 shares, decreasing direct ownership by 0.96% to 5,681,366 unitsForm 4Shares withheld for taxes or exercise price
- Aug 1, 2025LABPresident & CEO Egholm Michael was granted 3,000,000 shares, increasing direct ownership by 110% to 5,736,285 unitsForm 4Grant or award
- May 28, 2025LABPresident & CEO Egholm Michael covered exercise/tax liability with 9,906 shares, decreasing direct ownership by 0.36% to 2,731,285 unitsForm 4Shares withheld for taxes or exercise price
- May 23, 2025-$5,150LABPresident & CEO Egholm Michael sold $5,150 worth of shares (5,473 units at $0.94), decreasing direct ownership by 0.20% to 2,741,191 unitsForm 4Open-market sale
- May 22, 2025-$5,126LABPresident & CEO Egholm Michael sold $5,126 worth of shares (5,116 units at $1.00), decreasing direct ownership by 0.19% to 2,746,664 unitsForm 4Open-market sale
- May 23, 2025~$5,152LABMichael Egholm plans to sell 5,473 shares (~$5,152)Form 144Planned sale
- May 21, 2025-$4,861LABPresident & CEO Egholm Michael covered exercise/tax liability with 18,343 shares and sold $4,861 worth of shares (4,719 units at $1.03), decreasing direct ownership by 0.83% to 2,751,780 unitsForm 4Shares withheld for taxes or exercise priceOpen-market sale
- Apr 4, 2025LABPresident & CEO Egholm Michael converted options into 196,512 shares and covered exercise/tax liability with 57,676 shares, increasing direct ownership by 5% to 2,774,842 unitsForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Mar 21, 2025LABPresident & CEO Egholm Michael was granted 1,188,333 shares, increasing direct ownership by 82% to 2,636,006 unitsForm 4Grant or award
- Feb 20, 2025LABPresident & CEO Egholm Michael covered exercise/tax liability with 31,031 shares, decreasing direct ownership by 2% to 1,447,673 unitsForm 4Shares withheld for taxes or exercise price
- Nov 20, 2024LABPresident & CEO Egholm Michael covered exercise/tax liability with 28,795 shares, decreasing direct ownership by 2% to 1,473,704 unitsForm 4Shares withheld for taxes or exercise price
- Aug 20, 2024LABPresident & CEO Egholm Michael covered exercise/tax liability with 29,093 shares, decreasing direct ownership by 2% to 1,502,499 unitsForm 4Shares withheld for taxes or exercise price
- May 20, 2024LABEgholm Michael was granted 1,000,000 shares, increasing direct ownership by 188% to 1,531,592 unitsForm 4Grant or award
- Apr 8, 2024LABEgholm Michael covered exercise/tax liability with 102,564 shares, decreasing direct ownership by 16% to 531,592 unitsForm 4Shares withheld for taxes or exercise price
- Apr 5, 2024LABEgholm Michael was granted 221,132 shares and converted options into 196,512 shares, increasing direct ownership by 193% to 634,156 unitsForm 4Grant or awardExercise or conversion of a derivative
- Apr 4, 2023LABSEC Form 4 filed by Egholm MichaelForm 4Exercise or conversion of a derivative
- Jun 16, 2022ISOSEC Form 4 filed by Egholm MichaelForm 4Grant or award
- Apr 4, 2022LABSEC Form 4 filed by Egholm MichaelForm 4Grant or award
- Apr 4, 2022LABSEC Form 3: New insider Egholm Michael claimed ownership of 5,000 sharesForm 3New insider
Also sits on boards with
Officers and directors who share two or more companies with Michael Egholm.
Compare Michael Egholm with
- Michael Egholm vs Sean Mackay2 shared
- Michael Egholm vs Thomas D. Carey1 shared
- Michael Egholm vs Hanjoon Alex Kim1 shared
- Michael Egholm vs Frank Witney1 shared
- Michael Egholm vs Eli Casdin1 shared
- Michael Egholm vs Troy Cox1 shared
Other insiders at the same companies
- Thomas D. CareyLAB
- Hanjoon Alex KimLAB
- Frank WitneyLAB
- Eli CasdinLAB
- Troy CoxLAB
- Kathy L HibbsLAB
- Fenel M EloiLAB
- Casdin Partners Master Fund, L.P.LAB
Questions about Michael Egholm
- What is Michael Egholm's role at Standard Biotools Inc.?
- Michael Egholm reports to the SEC as president & CEO and director at Standard Biotools Inc. (LAB), according to the latest filing on August 24, 2026. Michael Egholm has also filed as director at IsoPlexis Corp (ISO).
- How many shares does Michael Egholm own?
- After the latest filing that states it, Michael Egholm directly owned 6,137,704 shares of Standard Biotools Inc. (LAB). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Michael Egholm bought or sold stock recently?
- The most recent open-market sale was on May 23, 2025: sold 5,473 shares of Standard Biotools Inc. (LAB) for $5,150 at an average of $0.94.
- How do I get alerts when Michael Egholm files?
- Follow Michael Egholm on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Michael Egholm filed 1 time in the last 90 days.
From SEC Forms 3, 4, 5 and 144 filed by Michael Egholm (SEC CIK 0001559779). Totals count each trade once, skipping amendments whose original is on file, from Apr 6, 2022 on. View on SEC EDGAR